Royal Bank of Canada
SMMT icon

Royal Bank of Canada’s Summit Therapeutics SMMT Stock Holding History

Royal Bank of Canada’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116K Buy
7,951
+529
+7% +$9.38K ﹤0.01% 5312
2026
Q1 		$141K Buy
7,422
+4,226
+132% +$68.3K ﹤0.01% 4931
2025
Q4 		$56K Sell
3,196
-182,617
-98% -$3.44M ﹤0.01% 5496
2025
Q3 		$3.84M Buy
185,813
+99,319
+115% +$2.41M ﹤0.01% 2877
2025
Q2 		$1.84M Buy
86,494
+84,613
+4,498% +$1.93M ﹤0.01% 3380
2025
Q1 		$36K Sell
1,881
-1,918
-50% -$38.5K ﹤0.01% 5691
2024
Q4 		$68K Sell
3,799
-106,135
-97% -$2.06M ﹤0.01% 5540
2024
Q3 		$2.41M Buy
109,934
+93,189
+557% +$1.3M ﹤0.01% 2848
2024
Q2 		$130K Buy
16,745
+5,288
+46% +$28.6K ﹤0.01% 5098
2024
Q1 		$47K Sell
11,457
-21,838
-66% -$86.8K ﹤0.01% 5571
2023
Q4 		$87K Buy
33,295
+13,816
+71% +$28.4K ﹤0.01% 5701
2023
Q3 		$36K Buy
19,479
+7,331
+60% +$14K ﹤0.01% 5951
2023
Q2 		$30K Buy
12,148
+11,524
+1,847% +$21K ﹤0.01% 6016
2023
Q1 		$1K Sell
624
-1,969
-76% -$5.37K ﹤0.01% 6931
2022
Q4 		$11K Buy
+2,593
New +$4.72K ﹤0.01% 6518
2022
Q2 		– Sell
-1,620
Closed -$4K – 7684
2022
Q1 		$4K Sell
1,620
-4,226
-72% -$10.7K ﹤0.01% 7336
2021
Q4 		$15K Buy
5,846
+2,536
+77% +$12.2K ﹤0.01% 6920
2021
Q3 		$17K Buy
3,310
+1,771
+115% +$12.7K ﹤0.01% 6774
2021
Q2 		$11K Buy
1,539
+1,518
+7,229% +$9.96K ﹤0.01% 6844
2021
Q1 		$0 Buy
+21
New +$135 ﹤0.01% 7662
2018
Q4 		– Sell
-11,000
Closed -$24K – 7083
2018
Q3 		$24K Sell
11,000
-900
-8% -$2.07K ﹤0.01% 5588
2018
Q2 		$29K Hold
11,900
– – ﹤0.01% 5391
2018
Q1 		$154K Buy
11,900
+9,400
+376% +$117K ﹤0.01% 4464
2017
Q4 		$28K Hold
2,500
– – ﹤0.01% 5446
2017
Q3 		$31K Hold
2,500
– – ﹤0.01% 5707
2017
Q2 		$28K Buy
+2,500
New +$28.1K ﹤0.01% 5408

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Royal Bank of Canada's SMMT Position: Q2 2026 in Review

Royal Bank of Canada increased its Summit Therapeutics (SMMT) stake by 7.1% in Q2 2026, buying an estimated $9.38K and bringing the position to 7,951 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #5312.

Royal Bank of Canada first reported a position in SMMT in Q2 2017 and has held it in 26 quarters since. The position peaked at $3.84M in Q3 2025. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Royal Bank of Canada held 7,951 shares of Summit Therapeutics worth $116K as of Q2 2026.
  • Royal Bank of Canada bought 529 Summit Therapeutics shares in Q2 2026, an estimated $9.38K.
  • Summit Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #5312 holding.
  • Royal Bank of Canada first reported a position in Summit Therapeutics in Q2 2017 and has held it in 26 quarters since.
  • Royal Bank of Canada's Summit Therapeutics position peaked at $3.84M in Q3 2025.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.